Walvax Biotechnology

Company profile

Walvax Biotechnology company profile

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. The company was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.